Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

D3821

Sigma-Aldrich

Devazepide

≥98% (HPLC), powder

Sinonimo/i:

(S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L-364,718, MK 329

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C25H20N4O2
Numero CAS:
103420-77-5
Peso molecolare:
408.45
Numero MDL:
MFCD00864500
Codice UNSPSC:
12352200
ID PubChem:
329798778
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated

Colore

white to off-white

Solubilità

DMSO: >5 mg/mL

Ideatore

Merck & Co., Inc., Kenilworth, NJ, U.S.

Temperatura di conservazione

2-8°C

Stringa SMILE

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15

InChI

1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
NFHRQQKPEBFUJK-HSZRJFAPSA-N

Descrizione generale

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

Applicazioni

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Azioni biochim/fisiol

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.
Devazepide is a CCK1 receptor antagonist.
Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.

Caratteristiche e vantaggi

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H300

Classi di pericolo

Acute Tox. 1 Oral

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
010M4600V
010M4600

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 2

1 of 2

Kit di rivelazione di citotossicitàPLUS (LDH) sufficient for 400 multiwell tests (04744926001), sufficient for 2,000 multiwell tests (04744934001), kit of 1 (4 components), suitable for protein quantification, suitable for cell analysis, detection

Roche

CYTODET-RO

Kit di rivelazione di citotossicitàPLUS (LDH)

Tiazolil blu tetrazolio bromuro 98%

Sigma-Aldrich

M2128

Tiazolil blu tetrazolio bromuro

X-M Wu et al.
Journal of animal physiology and animal nutrition, 96(2), 214-219 (2011-03-29)
Total parenteral nutrition (TPN) results in atrophy of the pancreas, while cholecystokinin (CCK) can significantly stimulate the exocrine pancreas in rodents. This study was designed to examine whether CCK may improve the atrophy of the pancreas in rats on TPN
Clémence Blouet et al.
PloS one, 7(12), e51898-e51898 (2012-12-20)
Previous evidence indicates that duodenal lipid sensing engages gut-brain neurocircuits to determine food intake and hepatic glucose production, but a potential role for gut-brain communication in the control of energy expenditure remains to be determined. Here, we tested the hypothesis
Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides
Staljanssens D, et al.
Peptides, 68, 219-227 (2015)
Kaleeckal G Harikumar et al.
Assay and drug development technologies, 9(4), 394-402 (2011-03-15)
The success in screening for drug candidates is highly dependent on the power of the strategy implemented. In this work, we report and characterize a novel fluorescent benzodiazepine antagonist of the type 1 cholecystokinin receptor (3-(3-(7-fluoro-1-(2-isopropyl(4-methoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)ureido)benzoic acid) that can be
Shannon A Metcalf et al.
Peptides, 32(6), 1296-1302 (2011-05-12)
One of the possible mechanisms by which the weight-reducing surgical procedure ileal interposition (II) works is by increasing circulating levels of lower gut peptides that reduce food intake, such as glucagon like peptide-1 and peptide YY. However, since this surgery
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.